Yellon DM - Search Results

1

Nitric oxide as a mediator of delayed pharmacological (A(1) receptor triggered) preconditioning; is eNOS masquerading as iNOS?

Bell RM, Smith CC, Yellon DM. Bell RM, et al. Among authors: yellon dm. Cardiovasc Res. 2002 Feb 1;53(2):405-13. doi: 10.1016/s0008-6363(01)00472-2. Cardiovasc Res. 2002. PMID: 11827691

2

Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion.

Liao Z, Brar BK, Cai Q, Stephanou A, O'Leary RM, Pennica D, Yellon DM, Latchman DS. Liao Z, et al. Among authors: yellon dm. Cardiovasc Res. 2002 Mar;53(4):902-10. doi: 10.1016/s0008-6363(01)00531-4. Cardiovasc Res. 2002. PMID: 11922900

3

PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning.

Mocanu MM, Bell RM, Yellon DM. Mocanu MM, et al. Among authors: yellon dm. J Mol Cell Cardiol. 2002 Jun;34(6):661-8. doi: 10.1006/jmcc.2002.2006. J Mol Cell Cardiol. 2002. PMID: 12054853

4

Spotlight on preconditioning.

Yellon DM, Downey JM. Yellon DM, et al. Cardiovasc Res. 2002 Aug 15;55(3):425-8. doi: 10.1016/s0008-6363(02)00488-1. Cardiovasc Res. 2002. PMID: 12160939 No abstract available.

5

Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?

Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Hausenloy DJ, et al. Among authors: yellon dm. Cardiovasc Res. 2002 Aug 15;55(3):534-43. doi: 10.1016/s0008-6363(02)00455-8. Cardiovasc Res. 2002. PMID: 12160950

6

The carboxyl-terminal activation domain of the STAT-1 transcription factor enhances ischemia/reperfusion-induced apoptosis in cardiac myocytes.

Stephanou A, Scarabelli TM, Townsend PA, Bell R, Yellon D, Knight RA, Latchman DS. Stephanou A, et al. FASEB J. 2002 Nov;16(13):1841-3. doi: 10.1096/fj.02-0150fje. Epub 2002 Sep 5. FASEB J. 2002. Retraction in: FASEB J. 2018 Apr;32(4):2315. doi: 10.1096/fj.02-0150fjeRET. PMID: 12223448 Retracted.

7

Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury.

Maddock HL, Mocanu MM, Yellon DM. Maddock HL, et al. Among authors: yellon dm. Am J Physiol Heart Circ Physiol. 2002 Oct;283(4):H1307-13. doi: 10.1152/ajpheart.00851.2001. Am J Physiol Heart Circ Physiol. 2002. PMID: 12234780 Free article.

8

The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart.

Bell RM, Maddock HL, Yellon DM. Bell RM, et al. Among authors: yellon dm. Cardiovasc Res. 2003 Feb;57(2):405-15. doi: 10.1016/s0008-6363(02)00675-2. Cardiovasc Res. 2003. PMID: 12566113

9

Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway.

Bell RM, Yellon DM. Bell RM, et al. Among authors: yellon dm. J Am Coll Cardiol. 2003 Feb 5;41(3):508-15. doi: 10.1016/s0735-1097(02)02816-4. J Am Coll Cardiol. 2003. PMID: 12575984 Free article.

10

Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS.

Bell RM, Yellon DM. Bell RM, et al. Among authors: yellon dm. J Mol Cell Cardiol. 2003 Feb;35(2):185-93. doi: 10.1016/s0022-2828(02)00310-3. J Mol Cell Cardiol. 2003. PMID: 12606259

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

481 results

Search Page

Filters